GAROFALO ELIZABETH A. — SEC Form 4 filings
SEC reporting owner CIK 1826361. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-17.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-11 to 2026-06-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 8,611 shares, $226,817 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 2,092 shares @ $45.69 ($95,583) in Xenon Pharmaceuticals Inc., filed 2024-03-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | Director | 5 | — | 2 legs · 6,519 sh · $131,234 | 12 |
| Xenon Pharmaceuticals Inc. (XENE) | Director | 4 | — | 1 leg · 2,092 sh · $95,583 | 10 |
| Alector, Inc. (ALEC) | Director | 3 | — | — | 5 |
Form 4 filings — GAROFALO ELIZABETH A.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | Alector, Inc. (ALEC) | Grant/award (A): 28,700 @ $0 · Grant/award (A): 9,450 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2025-09-03 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Sale (S): 1,600 @ $25.98 | EDGAR |
| 2025-06-12 | 4 | Alector, Inc. (ALEC) | Grant/award (A): 28,700 @ $0 · Grant/award (A): 9,450 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Sale (S): 4,919 @ $18.23 | EDGAR |
| 2024-06-12 | 4 | Alector, Inc. (ALEC) | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2024-06-05 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 15,542 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 6,652 · Option exercise (M): 6,652 (derivative) @ $0 · Grant/award (A): 15,959 (derivative) @ $0 · Grant/award (A): 9,387 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 3,500 @ $18.56 · Tax withholding (F): 1,408 @ $46.16 · Sale (S): 2,092 @ $45.69 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1826361 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →